Usefulness of Intraperitoneal Administration of Cisplatin Using a Reservoir for Advanced Gastric Cancer Complicated by Peritoneal Dissemination

  • Keiichiro Ohta
  • Shigekazu Ohyama
  • Takashi Takahashi
  • Toshifusa Nakajima


Although the results of treating gastric cancer have improved considerably as the number of early cancers has increased, at the present time most advanced gastric cancers that have invaded the serosa continue to give rise to peritoneal recurrence even when curative resection is possible [1]. We have been using subcutaneously implanted peritoneal reservoirs to perform postoperative intraperitoneal chemotherapy, chiefly with cis-diammine dichloroplatinum (CDDP), to treat intraoperative lavage cytology-positive gastric cancers (presumed to be positive for latent peritoneal dissemination) and obviously peritoneal dissemination-positive cases. We report the results and the usefulness of CDDP herein. The terminology used in based on the 12th edition of the General Rules for the Gastric Cancer Study.


Gastric Cancer Advanced Gastric Cancer Intraperitoneal Administration Peritoneal Dissemination Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ota K, Nakajima T, Ishihara S, Oyama S, Wakabayashi K, Nishi M (1994) Treatment of recurrent gastric cancer. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 21:1806–1812Google Scholar
  2. 2.
    Koike H, Konishi T, Mafune K, Hirata T, Miyama T, Hiraishi M, Idezuki Y (1989) Effect of sequential MTX/5-FU therapy for a case of disseminated intravascular coagulation syndrome associated with recurrence of gastric cancer: a case report. Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 90:1117–1121Google Scholar
  3. 3.
    Speyer JL (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12 (Suppl 4):23–28PubMedGoogle Scholar
  4. 4.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruiji EA, Graves T, Mullins RE, Schlag P (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16 (Suppl 6):83–97PubMedGoogle Scholar
  5. 5.
    Zimm S, Cleary SM, Lucas WE, Weiss RJ, Markman M, Andrews PA, Schiefer MA, Kim S, Horton C, Howell SB (1998) Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res 47:1712–1716Google Scholar
  6. 6.
    Howell SB (1988) Intraperitoneal chemotherapy for ovarian carcinoma. J Clin Oncol 6:1673–1675PubMedGoogle Scholar
  7. 7.
    Hirabayashi K (1989) Intraperitoneal chemotherapy. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 16:180–186Google Scholar
  8. 8.
    Kobayashi K, Fujimoto S, Takahashi M, Muto T, Toyosawa T (1998) Clinical result of intraperitoneal hyperthermic chemoperfusion for gastric cancer with serosal invasion to prevent peritoneal recurrence. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 25:1436–1438Google Scholar
  9. 9.
    Fujimura T, Yonemura Y, Nakagawara H, Fujita H, Itoh H, Hirono Y, Kinami S, Kaji M, Nakai M, Fushida S, Sugiyama K, Nishimura G, Miyazaki I (1995) Chemohy-perthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 22:1610–1612Google Scholar
  10. 10.
    Kano T, Kawami H, Kohdono S, Oka N, Inokuchi K (1990) Intraoperative intraperitoneal administration of CDDP against gastric cancer with peritoneal dissemination. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 17:233–237Google Scholar
  11. 11.
    Nakajima T, Kokaji A, Nonami T, Kajitani T (1981) Intraperitoneal chemotherapy for the peritoneal dissemination of gastric cancer. J Clin Surg 36:213–219Google Scholar
  12. 12.
    Coldman AJ, Goldie JH (1987) Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 14 (Suppl 4):29–33PubMedGoogle Scholar
  13. 13.
    Murray N (1987) The importance of dose and dose intensity in lung cancer chemotherapy. Semin Oncol 14:20–28PubMedGoogle Scholar
  14. 14.
    Takashima S, Doihara H, Yokoyama N, Tanada M, Soga H, Kurita A, Takiyama W, Saeki H, Moriwaki S (1990) Intraperitoneal administration of recombinant interferon-beta for prevention in peritoneal metastasis of gastric cancer. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 17:1600–1603Google Scholar
  15. 15.
    Sugimachi K, Maehara Y, Akazawa K, Kondo Y, Kunii Y, Kitamura M, Yamaoka H, Takahashi Y, Kito T, Katou M, Furukawa H, Takashima S (1994) Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study. Cancer Chemother Pharmacol 33:336–370CrossRefGoogle Scholar
  16. 16.
    Xu RH, Kalechman Y, Albeck M, Sredni B (1995) The cytoprotective effect of the immunomodulation AS101 against hydrochloride induced gastric lesions. Res Commun Mol Pathol Pharmacol 87:4–20PubMedGoogle Scholar
  17. 17.
    Sasaki M, Ogita M, Akasaka Y (1989) Ten-year survival rates of intraoperative intraperitoneal high-dose MMC lavage therapy for gastric cancer. Karkinos 2:931–936Google Scholar
  18. 18.
    Terashima M, Ikeda K, Takagane A, Sasaki N, Abe K, Araya M, Nishizuka S, Yonezawa H, Irinoda T, Nakaya T, Oyama K, Saito K (1998) Pharmacokinetic analysis of low-dose intra-peritoneal cis-platinum administration. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 25:1433–1435Google Scholar
  19. 19.
    Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, Kitajima M (1996) Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol 62:135–138PubMedCrossRefGoogle Scholar
  20. 20.
    Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R (1994) Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12:970–974PubMedGoogle Scholar
  21. 21.
    Jones AL, Trott P, Cunningham D, Rosin RD, Coleman D, Sauven P, Glazer G, Cunningham D, Hermon-Taylor J, Coombes RC, Stein R, Parker M, Kirkham J (1994) A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 5:123–126PubMedCrossRefGoogle Scholar
  22. 22.
    Tsujitani S, Okuyama T, Watanabe A, Abe Y, Maehara Y, Sugimachi K (1993) Intraperitoneal cisplatin during surgery for gastric cancer and peritoneal seeding. Anti-cancer Res 13:1831–1834Google Scholar
  23. 23.
    Cascinu S, Valentini G, Catalano G (1993) A pilot clinical trial of postoperative adjuvant intraperitoneal cisplation, 5-fluorouracil, 6S-leucovorin and interferon alpha 2b in patients with resected gastric cancer. Tumori 79:331–335PubMedGoogle Scholar
  24. 24.
    Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, Trochanowshi B, Lin S. Toomasi F, Brennan M (1993) Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 11:425–433PubMedGoogle Scholar
  25. 25.
    Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354PubMedCrossRefGoogle Scholar
  26. 26.
    Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, Baranda J, Casagrande Y, Groshen S, Silberman H (1997) Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 79:1767–1775PubMedCrossRefGoogle Scholar
  27. 27.
    Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan MF (1996) Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14:1818–1828PubMedGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Keiichiro Ohta
    • 1
  • Shigekazu Ohyama
    • 1
  • Takashi Takahashi
    • 1
  • Toshifusa Nakajima
    • 1
  1. 1.Department of SurgeryCancer Institute HospitalTokyoJapan

Personalised recommendations